EDIT vs INTU · rev $32.3M vs P/E 64, rev $18.83B
Editas Medicine Inc (EDIT) versus Intuit Inc (INTU) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Intuit Inc (INTU) is a software - application company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported INTU revenue for 2025-07-31 was $18.83B. Net income was $3.87B. INTU currently screens at market cap $217.76B and trailing P/E 63.7.
EDIT currently screens at market cap $375.2M. INTU currently screens at market cap $217.76B and trailing P/E 63.7.
Not investment advice. Open the EDIT and INTU stock pages for the full models.
Not investment advice.